Loading the content... Loading depends on your connection speed!

HIV/AIDS HOTLINE: 1-800-FLA-AIDS
Why is No One on The First Treatment to Prevent H.I.V.?

Why is No One on The First Treatment to Prevent H.I.V.?In November, 2010, the New England Journal of Medicine published the results of a three-year clinical trial, funded by the National Institutes of Health, announcing the arrival of a treatment that could reduce the risk of contracting H.I.V. by more than ninety per cent. The treatment involved a blue, oval pill containing emtricitabine and tenofovir. Marketed under the brand name Truvada, the pill was synthesized in 2004 by Gilead Sciences, the world’s largest producer of branded H.I.V. drugs, and has been used in combination with other antiretrovirals as a primary treatment for people living with AIDS. The N.I.H. team discovered that a daily dose of Truvada not only suppressed the virus in people who were already infected but also prevented healthy people from contracting H.I.V. in the first place. Following the N.I.H. study, which tracked gay men in Peru, Ecuador, Brazil, South Africa, Thailand, and the United States, additional trials showed the drug to be effective for heterosexual men and women, as well as for injection-drug users. Researchers called the treatment “pre-exposure prophylaxis,” or PrEP for short. Others have called it “the new condom.”

Read the full article at  New Yorker.com

Comments are closed.

Mobile version: Enabled